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Os vírus herpes simplex (HSV) são vírus ubíquos, adaptados ao hospedeiro, e responsáveis por 
diversas patologias. Existem dois subtipos: HSV-1, tradicionalmente associado a infeções a nível 
orofacial, e HSV-2, o qual é maioritariamente associado a úlceras genitais. Esta distinção é cada vez 
menos evidente, dada a emergência de infeções genitais causadas pelo HSV-1, associada sobretudo 
a fatores sociais, demográficos e migratórios, o que torna o herpes genital uma das infeções 
sexualmente transmissíveis mais prevalentes mundialmente. 
Uma melhor compreensão das infeções genitais causadas pelo HSV-1 e HSV-2 é mandatória para 
entender a patogenicidade das doenças herpéticas. Esta tese teve como objetivo avaliar o ciclo de vida 
de vários isolados clínicos genitais de HSV-1 e HSV-2 com diferentes cargas virais, em linhas celulares 
distintas, dando ênfase à capacidade e eficiência da infeção viral, em termos de taxa de replicação e 
progenia. 
Os nossos resultados mostraram que: i) ambos os subtipos do HSV apresentam um padrão de 
infeção semelhante independentemente da MOI, com DNA a ser sintetizado 6-12h pós-infeção; ii) 
independentemente do subtipo, a concentração inicial do vírus aparentemente não afeta a sua 
capacidade de adesão a qualquer linha celular; iii) as células Vero E6 mostraram-se as mais 
apropriadas para a infeção do HSV-2; iv) as células HeLa229 mostraram ser as mais apropriadas para 
a infeção do HSV-1 com cargas virais menores; e v) as células Vero apresentaram os piores resultados 
de infeção viral para ambos os subtipos. Em geral, o HSV-2 mostrou sempre menores capacidades de 
aderência e taxas de crescimento que o observado para o HSV-1, apesar de se terem observado 
maiores progenias na linha celular Vero E6. 
Em conclusão, os resultados apresentados nesta tese de mestrado irão certamente contribuir para 
um melhor conhecimento da patogenicidade das infeções genitais causadas pelo herpes. 
 
 
























































Herpes simplex viruses (HSV) are ubiquitous host-adapted pathogens that cause a variety of 
different disorders. There are two sub-types: HSV-1, which is traditionally associated with oro-facial 
infections, and HSV-2 that is mostly associated with genital ulcers. This distinction, however, is 
becoming less evident since HSV-1 frequency in genital infections is increasing due to social, 
demographic and migratory tendencies, making genital herpes one of the most prevalent sexually 
transmitted infections worldwide. 
A better understanding on genital HSV-1 and HSV-2 infections is mandatory to the pathogenesis of 
human herpes disease. The scope of this thesis was to evaluate the life cycle of various HSV-1 and 
HSV-2 genital clinical isolates with different viral loads in three distinct host cell lines, giving special 
focus on both capacity and efficiency of viral infection, in terms of replication rate and progeny. 
Our results showed that: i) both HSV-1 and HSV-2 isolates exhibited similar infection patterns 
regardless MOI, with DNA starting to be synthesized nearly at 6-12h post-infection; ii) regardless HSV 
subtype, initial viral concentrations do not apparently affect adherence to any host cell line nor the 
generated progeny; iii) Vero E6 cells seemed the most appropriated cell line for HSV-2 infection; iv) 
HeLa229 cells appeared to be the most suitable for HSV-1 infection for smaller inoculums; and v) Vero 
cell line had the worst viral growth results for both HSV subtypes. In general, HSV-2 displayed always 
lower both attachment capacities and growth rates than HSV-1, although higher progenies were seen 
in Vero E6 cell line.      
Overall, the findings presented in this MSc thesis will certainly constitute a step forward for the 
understanding of the pathogenesis of the human herpes genital infections. 
 
 

























































This MSc thesis is divided into 4 chapters that encompass: 
 
i) a general introduction (Chapter 1) that intends to briefly describe the biology of Herpes Simplex 
Virus (HSV), in particular the current knowledge on HSV infections, clinical outcomes and infectious 
life cycle. The issues focused on this chapter aim to put into context and to emphasize the relevance 
of the study described throughout the thesis. Ultimately, the detailed aims of the present MSc thesis 
are presented; 
 
ii) a section of materials and methods (Chapter 2) describing, in detail, the methodology used in 
the present thesis, including preliminary assays done for optimizing the experimental conditions for 
the current study; 
 
iii) a results section (Chapter 3), where the main findings of the current study are presented, in 
order to better understand whether the HSV host cell invasion process depends on the genital HSV 
sub-type/strain or on the infected cell line, in terms of capacities of infections, replication rates, and 
progenies. 
 
iv) an overall discussion and final conclusions (Chapter 4) where the major findings of the 
performed study are highlighted and discussed in a general context, taking into account the scope 






The study presented on this thesis resulted on the following scientific communication: 
 
A. Azevedo, A. Nunes, C. Roque, I. Costa, JP Gomes, S. Lopo. 2016. Molecular studies on HSV: 
replication rate, infection capacity and progeny. 19th Annual European Society for Clinical Virology 
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RT-PCR – Real-time polymerase chain 
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Herpes simplex viruses (HSV) are important human pathogens that cause disease on a variety of 
different tissues. As members of the Herpesviridae family, they comprise four major components: (i) a 
core containing a linear double-stranded DNA (dsDNA) molecule (Pellet et al., 2003); (ii) an icosahedral 
capsid surrounding the core with 162 capsomers (Kukhanova et al., 2014); (iii) an amorphous structure 
asymmetrically distributed around the capsid designated tegument; and (iv) a host-derived lipid 
envelope with embedded viral glycoproteins on its surface (Kukhanova et al., 2014). Based on their 
biological properties, HSV can be further placed in the alphaherpesviridae subfamily due to their variable 
host range, short reproductive cycle, rapid spread in culture and ability to destroy infected cells (Wagner 
et al., 1997). 
Like other herpesviruses, HSV have the ability to remain latent in the host after a primary infection. 
During latency, the genome acquires a “dormant” state as a circular episome within cells and persists 
for the lifetime of the infected individual, evading detection by the immune system. Reactivation from 
latency is often induced by internal/external stimuli leading to productive infection and recurrence of 
disease (Boehmer et al., 2003, Nicoll et al., 2012). 
HSV can be divided into two sub-types, herpes simplex virus type 1 (HSV-1) mostly associated with 
epithelial cells of the skin and mucosa near the mouth; and herpes simplex virus type 2 (HSV-2), more 
related to genitalia (Stevens et al., 1971, Singh et al., 2005, Palmer, 2010).  
 
1.1. Transmission, Clinical Manifestations and Prevention/Therapy 
HSV transmission occurs by intimate contact with an infected individual and depends on the direct 
exposure of infectious mucous membranes or abraded skin with the virus, as infected individuals shed 
it mainly through saliva, tears and genital secretions (Chilukuri et al., 2003, Beauman, 2005, Lee, 2008). 
HSV-1 and HSV-2 are usually transmitted through different routes of infection, affecting different areas 
of the body, although the signs and symptoms can overlap (Whitley et al., 2001, Pellet et al., 2003, 
Roizman et al., 2003). Primary infection by both HSV has, in general, a more severe symptomatology 
than recurrent infections, leading to the establishment of long-term latency after the infection of sensory 
nerve endings (Chilukuri et al., 2003, Lee, 2008). Depending on whether the immune system has been 
compromised, HSV infections can have more severe consequences.  
Regarding HSV-1, the most common sites of infection are the skin and mucosal membranes. Oro-
facial lesions are characterized by the development of vesicles at the border of the lip (Figure 1.1A) that 
progress to a pustular or ulcerative state within 3 days. The infection is completely healed in 8 to 10 
days; however, viral shedding continues for 3 to 5 days after the lesions have healed (Esmann, 2001, 
Sciubba, 2003). Ocular lesions (Figure 1.1B) caused by HSV-1 are linked to a variety of ocular 
complications, being one of the leading causes of corneal blindness and keratoconjunctivitis (Whitley et 
al., 1998, Rudnick et al., 2002).  
On the other hand, HSV-2 infections are more associated with genital herpetic lesions and are 
currently one of the most prevalent sexually transmitted infections (STIs) worldwide (Smith et al., 2002). 
After acquisition of infection, macules and papules, followed by vesicles, pustules and ulcers appear 
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within a few days (Figure 1.1C), for a period that can last up to 6 weeks. Consequences in men are rare, 
but women can develop serious complications including aseptic meningitis or urinary retention. Primary 
infections can be associated with fever, dysuria, localized inguinal adenopathy, malaise and headaches 
(Whitley et al., 2001, Beauman, 2005). Over the past few years, there has been an increased 
consciousness on genital herpes due to the discovery of its association with the risk of human 
immunodeficiency virus (HIV) acquisition. The interactions between HSV-2 and HIV may result in a more 
efficient HIV transmission and in an increase in its replication rate and shedding during a HSV 
reactivation. The relationship between HSV-2 and HIV seems to be reciprocal, since HIV infections also 
increase HSV-2 reactivation and probably its acquirement (Beauman, 2005, Mayaud et al., 2008). 
Educational efforts must be developed for those at greater risk to prevent virus transmission: the use of 
condoms, for instance, should be promoted, as its use significantly decreases the probability of acquiring 
STIs.  
Neonatal HSV infections are also a very important matter, as they can result in serious morbidity and 
mortality (Rudnick et al., 2002). Neonate infections can occur in utero (5%), intrapartum (85-90%) or 
postnatally (5-10%) (Straface et al., 2012). Infections are usually symptomatic, with sores appearing in 
the skin, eyes and mouth (Figure 1.1D), and the possibility to affect multiple organs, leading to the baby’s 
death. Most of these infections are due to HSV-2, but 15 to 30% are found to be caused by HSV-1 
genital infections (Nahmias, 1970, Rudnick et al., 2002, Lee, 2008). 
Additionally, both HSV can infect the central nervous system (CNS) and cause diseases such as 
encephalitis and meningitis, being one of the most common causes of fatal sporadic encephalitis in 
humans. Patients may experience fever, malaise, headaches and personality fluctuations. The mortality 
among untreated patients exceeds 70%, decreasing in treated patients to 19%. However, more than 
50% of the patients who survive are left with moderate or severe neuropsychiatric sequels, as only 2.5% 
of the patients who survive regain normal neurological function (Whitley et al., 1998, Whitley et al., 2001, 















Figure 1.1: Herpesvirus induced lesions.  
[A] Oral herpes; [B] Ocular herpes; [C] Genital Herpes; [D] Neonatal herpes. 






Despite an increasing awareness regarding both HSV-1 and HSV-2 infections, many cases remain 
undiagnosed, as they are usually asymptomatic (silent transmission to partners or to the neonate) or 
unrecognized, when symptomatic infections are present in an unusual or atypical way, making the 
diagnosis harder (Roizman et al., 2003). 
Currently, there are several systemic antiviral agents against HSV. The most effective treatment is 
acyclovir or its prodrugs valacyclovir and famciclovir (Chilukuri et al., 2003, Pellet et al., 2003, Lee, 2008, 
Martinez et al., 2008). Even though these drugs can treat herpes disease, they cannot prevent 
reactivations. In addition, prolonged prophylaxis and treatment can result in the development of drug 
resistance, particularly in immunocompromised patients (Bacon et al., 2003).  
 
1.2. Epidemiology 
HSV infections occur worldwide, without seasonal variation. Despite the fact that infections caused 
by HSV are a serious health problem worldwide, few updated epidemiological data exist, with the most 
recent ones dating from 2012. Nevertheless, it is known that the prevalence of both HSV infections 
varies according to the subject’s age, country, regions and population subgroups (Smith et al., 2002).  
Regarding HSV-1, it has been estimated that 3.7 billion people under the age of 49 are globally 
infected with this subtype (Looker et al., 2015a). This prevalence was clearly higher in Africa, South-
East Asia and Western Pacific than for Europe, Americas and Western Mediterranean. However, a 
different scenario was seen for the HSV-1 genital infections, which seem to be globally increasing. Of 
the 3.7 billion prevalent cases, ~140 million correspond to prevalent genital HSV-1 infections, primarily 
in the Americas, Europe and Western Pacific (Looker et al., 2015a). 
Concerning HSV-2, the estimated worldwide prevalence among people between the ages of 15 and 
49 was 417 million (Looker et al., 2015b). Prevalence was higher in Africa (31.5%) and generally higher 
in females compared to males (14.8% vs. 8%). This difference is due to the fact that women have greater 
biological susceptibility to HSV-2, although different patterns of sexual behavior between the sexes can 
expose women to a higher risk of infection. Estimates also indicate that ~ 23 million new cases are 
diagnosed every year (Looker et al., 2008) 
Neonatal HSV has an estimated incidence of around one in 2000 to 5000 births per year, although 
in some areas there can be as many as one neonatal infection in 1500 deliveries. This incidence is 
directly related to the seroprevalence of HSV-2 (Looker et al., 2015a).  
 
1.3. Virion structure and Genomic organization 
The mature infectious HSV virion has four distinct structural components: the dsDNA genome is 
enclosed within an icosahedral capsid, surrounded by a proteinaceous tegument and a host-derived 







Figure 1.2: The HSV-1 virion. 
Electron micrograph of a negatively stained HSV-1 virion and a cartoon representation showing the 
components comprising the virion. Adapted from Roizman et al., 2003. 
 
1.3.1. Central core and Genome 
The HSV core contains a dsDNA molecule, with approximately 152 to 155 kilo base-pairs (kbp) and 
a 68.3%-70.4% G+C content (Szpara et al., 2014, Kolb et al., 2015). The genome comprises two 
covalently linked components, L (long) and S (short), with unique sequences UL (107.09 kbp) and US 
(12 kbp), respectively, flanked by large inverted repeats (Figure 1.3). The UL and US units of the genome 
can invert relative to one another, producing four different types of DNA molecules (Kukhanova et al., 
2014). The genes of the long and short unique sequences are designated UL1 to UL56, and US1 to 
US12, respectively. UL and US encode about 70 proteins, designated virion proteins (VP) and infected 







Figure 1.3: HSV genome structure. 
The long component of the genome (UL) is flanked by inverted repeats designated as a (black) and b (dark 
grey), and b’a’; the short component (US) is flanked by a’c’ and ca sequences. Adapted from Kukhanova et 
al., 2014. 
 
The genetic maps of both HSV genomes confirms the co-linearity and shows an overall identity of 
83% (Roizman et al., 2003). Nevertheless, the two genomes differ in the location of endonuclease 
cleavage sites in their genomic DNAs, in the apparent sizes of the encoded proteins, as well as in some 






During an HSV infection, the capsid plays a central role in delivering the genome of the virus into the 
host cell nucleus. The capsid, where DNA is stored, consists mainly of four proteins: VP5 (coded by the 
UL19 gene), VP19C (UL38), VP23 (UL18) and VP26 (UL35). VP5 is the major capsid protein and is 
present in both pentons, forming the vertices, and hexons, forming the faces (Baines, 2011). VP26 is 
present as a ring on top of the VP5 subunits of each hexon (Zhou et al., 1995), whereas triplexes made 
of one VP19C and two VP23 molecules link adjacent capsomers. One of the vertices is unique, 
consisting of 12 copies of the portal protein UL6 through which viral DNA is sent into the nucleus 
(Bowman et al., 2003, Roizman et al., 2003, Brown et al., 2011).  
Four types of capsids can be isolated from infected cells. First, spherical procapsids are formed, 
containing the internal scaffold. During infection, the maturation of procapsids gives rise to A-, B- and 
C-capsids. A-capsids lack both scaffold proteins and viral DNA, and are incapable of maturation; B-
capsids have scaffold proteins and are thought to be in an early stage of viral assembly; C-capsids 
contain the viral genome and can become infectious virions (Gibson et al., 1972, Sheaffer et al., 2001, 
Palmer, 2010, Tandon et al., 2015). 
 
1.3.3. Tegument 
The tegument occupies the space between the capsid and the envelope, and can be divided in inner 
tegument, which is tightly bound to the capsid, and outer tegument, connected to the viral envelope 
(Scrima et al., 2015). It occupies about two thirds of the volume enclosed within the virion (Grunewald 
et al., 2003) and is made of, at least, 20 different proteins. The tegument functions as a delivery 




The outer layer of the HSV virion is a host-derived envelope, consisting in a lipid bilayer with around 
13 virally encoded glycoproteins (g) embedded in it. HSV glycoproteins have roles in attachment and 
entry into the host cell, even though the function of each glycoprotein varies according to the overall 
pathogenesis and immune evasion strategy of the virus (Kukhanova et al., 2014). Nevertheless, it is 
known that gB, gC, gD, gH and gL are essential for the infection process (Reske et al., 2007).  
 
1.4. HSV life cycle 
HSV is thought to have a relatively short life cycle of about 15 to 24 hours (Jenkins et al., 1996, 
Lehman et al., 1999, Roizman et al., 2003, Schiffer et al., 2013) that can be divided in six major steps: 
(i) entry into the host cell, (ii) viral gene expression, (iii) viral DNA replication, (iv) viral maturation, (v) 
viral egress and (vi) latency. 
 
1.4.1. Entry into the host cell 
HSV has two ways of getting into the host cell: endocytosis, not yet fully understood; and membrane 





Figure 1.4: Pathways of HSV entry into the cell. 
Two major entry pathways are known for HSV entry: (I) entry by viral envelope fusion at the plasma 
membrane and (II) endocytosis. Both processes lead to the delivery of the HSV genome into the host cell 
(Salameh et al., 2012). 
 
Initial attachment/entry is mediated via gC (or gB, in case gC is unavailable), that binds to the cell 
surface’s glycosaminoglycans, in particular heparan sulfate (HS) (Campadelli-Fiume et al., 2012). 
Afterwards, gD interacts with one of the three entry receptors: (i)  the herpesvirus entry mediator 
(HVEM), a component of T and B-lymphocytes, epithelial cells and fibroblasts; (ii) both Nectin-1 and 
Nectin-2, members of the immunoglobulin family, expressed in human tissues including epithelial cells, 
fibroblasts and neurons, or (iii) the 3-O sulfated heparan sulfate (3-OS-HS), a polysaccharide present 
in endothelial cells (Figure 1.5) (Spear, 2004, Salameh et al., 2012, Kukhanova et al., 2014). Despite 
structural disparities and different interactions with gD, the binding to one of the three receptors 
described above leads to the same endpoint: membrane fusion (Heldwein et al., 2008, Gianni et al., 
2009, Kukhanova et al., 2014).  
The next step requires gB and the heterodimer gH/gL (Figure 1.5), resulting in the release of the 
capsid and of approximately 20 tegument proteins into the cell’s cytoplasm. The capsids and several 
tegument proteins are transported through the cell to the nucleus via microtubules, mediated by the 
retrograde motor dynein (Döhner et al., 2002, Palmer, 2010, Kukhanova et al., 2014). Once the capsids 
have reached the proximity of the nucleus, they dock at the nuclear pore, releasing the viral genome 
through the UL6 portal (Roizman et al., 2003, Kukhanova et al., 2014, Fay et al., 2015). Upon entry into 







Figure 1.5: Multiple receptors upon HSV entry. 
gC mediates the initial attachment of virus particles to HS. The next step involves the interactions between 
gD with HVEM, Nectin-1/Nectin-2 or 3-OS-HS, resulting in membrane fusion, later mediated by the gH-gL 
heterodimer, resulting in the release of the viral nucleocapsid into the host cell cytoplasm (Spear, 2004).  
 
1.4.2. Viral gene expression 
Once the nucleocapsid reaches the nucleus and the viral DNA ejects, transcription begins 
(Ramachandran, 2003). HSV, as all herpesvirus, has a controlled temporal cascade of gene expression, 
with three classes of genes, designated α (or IE – immediate early), β (or E – early) and γ (or L – late). 
All genes are transcribed using the host’s RNA polymerase II (Honess et al., 1974, Lee, 2008, Palmer, 
2010). The α genes begin to be expressed very soon after viral entry and α proteins reach their peak 2 
to 4 hours p.i., encoding proteins involved in the transcription of other viral genes. Transcripts are 
transported to the cytoplasm and translated into five proteins, being the most important one ICP0. 
Immediate early proteins accomplish multiple functions and perform dramatic reorganization of cellular 
processes in the interest of the virus (Boehmer et al., 2003, Kukhanova et al., 2014). β genes are 
expressed following the accumulation of α proteins, and their expression peaks around 5 to 7 hours p.i. 
encoding proteins responsible for viral DNA replication, and signaling the onset of viral DNA synthesis, 
which results in the expression of γ genes. The expression of the later genes typically peaks between 8 
and 12 hours p.i., and can be further divided in two sub-classes, γ1 and γ2, depending on their 








Figure 1.6: General pattern of gene expression during a HSV infection. 
The first genes to be expressed are α genes (purple) followed by β genes (blue). Meanwhile, DNA replication 
begins (dotted line). At this point, γ genes start to be expressed: γ1 (orange) can be expressed prior to DNA 
replication, and γ2 (green) requires DNA synthesis to be expressed. Once the proteins have accumulated, 
progeny viruses (red) assemble (Ramachandran, 2003). 
 
1.4.3. Viral DNA Replication 
DNA replication takes place after the expression of α and β genes, using the circularized DNA as 
template. The HSV genome contains three origins of replication (Figure 1.7): OriS, present twice in the 




Figure 1.7: HSV origins of replication. 
The figure shows the organization of the HSV genome, with the origins of replication shown as OriL and 
OriS. Both OriS and OriL are located in the promoter-regulatory regions of divergently transcribed genes: 
OriL between genes encoding replication proteins and OriS between genes encoding α proteins. Adapted 
from de Silva et al., 2009. 
 
The DNA is replicated using a virally-encoded replication complex comprising an origin-binding 
protein UL9; a single stranded DNA-binding protein ICP8 (UL29); the DNA polymerase and DNA 
polymerase processivity factor, UL30 and UL42, respectively; and the DNA helicase/primase (H/P) 
complex UL5, UL52 and UL8 (Lehman et al., 1999, Weller et al., 2012).  
The first stage of DNA replication involves an origin-UL9-dependent step. Upon DNA circularization, 
UL9 binds to specific recognition sites in either OriL or OriS and begins to unwind the viral DNA. UL9 
then recruits ICP8, resulting in the recruitment of the helicase-primase heterodimer, followed by the 
polymerase complex (Figure 1.8). The second stage of replication is UL9-independent, and leads to the 
formation of longer-than-unit length concatemers, later packaged into procapsids in the form of 






Figure 1.8: Model of HSV DNA replication. 
Replication fork model. The H/P complex, made of proteins UL5, UL8 and UL52, unwinds the DNA; the 
binding protein ICP8 binds to single-stranded template DNA; the polymerase (UL30) and its accessory 
protein UL42 promote leading and lagging-strand DNA synthesis. Adapted from Crumpacker et al., 2002. 
 
1.4.4. Viral maturation 
Following repeated rounds of DNA synthesis, concatemeric genomes accumulate within replication 
compartments. The synthesis of γ genes, encoding late proteins that include structural proteins, 
envelope proteins incorporated in nuclear membrane and several other structural and packaging 
proteins, lead to the assembly of new progeny virions (Lehman et al., 1999). Capsids are initially formed 
as procapsids with an internal protein scaffold made of UL26 and UL26.5 gene products, which is lost 
upon DNA packaging. The protease UL26 cleaves itself, generating capsid proteins VP24 and VP21, 
and UL26.5, generating VP22a (Newcomb et al., 2000, Mettenleiter et al., 2006). Capsid formation also 
requires the capsid proteins VP5, VP23 and VP19C (Mettenleiter et al., 2009). The procapsids differ 
from mature capsids in several aspects: while the procapsids are spherical, have a more porous 
structure with holes between capsomers and have oval hexons, mature capsids (A-, B- or C-) are 
icosahedral, have a less porous composition and have hexagonal hexons (Newcomb et al., 2000, 
Mettenleiter et al., 2006). Procapsids transform into mature capsids in a process in which the shell 
undergoes structural changes (Figure 1.9). Capsid maturation overlaps with viral DNA packaging, 
resulting in a mature C-capsid containing the viral genome. C-capsids are the only ones able to undergo 






Figure 1.9: HSV capsid maturation. 
The spherical procapsid is the precursor of all other capsid types. It is made primarily of VP5 pentons (dark 
blue) and hexons (light blue) linked by triplexes (green), with 12 copies of UL6 that will eventually form the 
portal. The inner scaffold shell is lost or degraded in A capsids, retained in B capsids, and replaced with 
DNA in C capsids. Adapted from Baines, 2011. 
 
1.4.5. Viral egress 
Successful encapsidation of the viral genome is followed by budding through the modified inner 
nuclear membrane (INM) into the perinuclear space to acquire the primary envelop and continue the 
maturation process (Kukhanova et al., 2014). Several models have been proposed over the years to 
explain the exact egress pathways; however, the most exact one is the envelopment-deenvelopment 
model. According to this, capsids dispersed in the nucleus approach and attach the INM, through 
intranuclear movement via nuclear actin filaments, induced by HSV infection (Mettenleiter et al., 2009). 
Proteins UL31 and UL34 are crucial for this process, since the UL31/UL34 nuclear envelopment 
complex induces conformational changes in the nuclear lamina. This disruption of the lamina allows the 
capsids to bud into the perinuclear space gaining a primary tegument and envelope (Figure 1.10A) 
(Newcomb et al., 2006, Kukhanova et al., 2014). 
Next, nucleocapsids undergo a de-envelopment process, by fusing with the outer nuclear membrane 
(ONM), resulting in the loss of the primary envelope and nucleocapsid release into the cytoplasm, for 
continuing maturation (Figure 1.10B) (Roizman et al., 2003, Mettenleiter et al., 2006, Mettenleiter et al., 
2009). 
After nuclear egress, the nucleocapsids have to acquire tegument proteins and the final (secondary) 
envelope in order to exit the cell (Mettenleiter et al., 2009). This process occurs predominantly in the 
cytoplasm, and is controlled by a complex network of protein-protein interactions (Owen et al., 2015). 
HSV nucleocapsids make their way toward cytoplasmic vesicles derived from the trans-Golgi Network 
(TGN) to reacquire their envelop (Figure 1.10C). 
Currently, little is known about the mechanism by which mature virions are released from cells, but 
it is thought that these viruses use proteins from the host cell’s secretory pathway to facilitate egress at 
the plasma membrane. The virus-containing secretory vesicles move to the plasma membrane, where 
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they fuse and release mature virions, by exocytosis, resulting in the death of the host cell (Figure 1.10D) 




Figure 1.10: HSV viral egress. 
[A] Primary Envelopment - After capsids are formed in the nucleus, they bud into the INM to form an 
enveloped particle in the perinuclear space; 
[B] De-envelopment - HSV particles reside in the perinuclear space. HSV glycoproteins gB and gH/gL 
mediate fusion of the viral envelope with the ONM; 
[C] Secondary Envelopment - In the cytosol, capsids coated with numerous tegument proteins bind onto 
the surface of the TGN that contains HSV glycoproteins. Interactions between all of these proteins promote 
envelopment; 
[D] Egress - Virions are transported to cell surface in exocytic vesicles, leading to the death of the host cell. 
Adapted from Johnson et al., 2011). 
 
1.4.6. Latency-Reactivation Cycle 
Herpesvirus have the ability to establish latency, one of the most intellectually challenging aspects 
of HSV biology (Stevens et al., 1971). Despite a vigorous immune response during an infection, HSV 
establishes latency in sensory neurons, typically trigeminal ganglia for HSV-1 and sacral ganglia for 
HSV-2. Remarkably, up to 40% of sensory neurons can be latently infected (Kramer et al., 1998, Perng 
et al., 2010, Nozawa et al., 2014).  
The latency-reactivation cycle can be divided into three major steps: (i) establishment, (ii) 
maintenance, and (iii) reactivation. Establishment of latency includes the entry of the viral genome into 
a sensory neuron, through retrograde axonal transport (Figure 1.11). Viral gene expression is silenced 
with the exception of one set of transcripts that continue to be expressed known as latency-associated 
transcripts (LAT) (Nicoll et al., 2012, Ma et al., 2014). Maintenance of latency is a phase that lasts as 
long as the host lives, and is defined as a period when infectious genes are not detected, but LATs 
continue to be expressed. The full length 8.3 kbp LAT is transcribed from the latency associated 
promoter and is sliced, giving rise to two stable 2.0 kb and 1.5 kb introns (Nicoll et al., 2012, Kukhanova 
et al., 2014). These two LAT forms accumulate in the nuclei of latently infected neurons and are directly 
anti-sense to HSV lytic protein ICP0, preventing viral gene transcription through a  slow and multistep 
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process that results in the decrease of α genes expression (Jackson et al., 2003). During latency, the 
viral genome circularizes and is maintained as an episome within the nucleus (Ramachandran, 2003). 
In Humans, latency is maintained throughout the host’s life, indicating that a well-conceived strategy 
exists, allowing periodic reactivation, while maintaining the viral genome in sensory neurons. 
Reactivation from latency is initiated by an external stimulus, such as stress or immunosuppression, 
culminating in viral gene expression. Clinically, depending on the host immune status, reactivation can 
be symptomatic, where the virus can be detected in peripheral tissues and disease is recognized, 
resulting in lesions, or asymptomatic, where the virus can be laboratory detected but signs of disease 
are unrecognized. In both cases, the virus is carried by anterograde axonal transport (Figure 1.11) to 
peripheral tissues through the motor protein kinesin, usually to cells at, or near the site of initial infection. 




Figure 1.11:  Neural trafficking during latency-reactivation cycle. 
HSV establishes latent infection in the nuclei of peripheral ganglia, following retrograde transport along 
microtubules, through the dynein transport protein. Reactivation results in the production of new virions that 
undergo anterograde transport back to peripheral tissues with the transport protein kinesin. Adapted from 
Owen et al., 2015. 
 
1.5.  Scope of the Thesis 
HSV infects a variety of host cells, including lymphocytes, epithelial cells, fibroblasts, and neurons 
(Connolly et al., 2011). Although there are multiple studies that try to evaluate the infection patterns of 
HSV, including among sub-types, none of them is conclusive and reproducible, being even sometimes 
contradictory (Docherty et al., 1971, Tada et al., 1977, Nguyen et al., 2005, Aguilar et al., 2006). For 
instance, even though HSV is considered to have a relatively short life cycle when compared with other 
viruses, there doesn’t seem to be a consensus regarding the duration of the infectious process, as 
cycles ranging from 15 to 24 hours can be currently found throughout the literature (Jenkins et al., 1996, 
Lehman et al., 1999, Roizman et al., 2003, Schiffer et al., 2013). Moreover, it is also not known whether 
HSV-1 or HSV-2 strains display different infectious patterns and virulence depending on the host 
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infected tissue (oro-facial tissue versus genitalia), even though it is known that HSV-1 genital 
reactivations appear to be less common and timely shorter than those of HSV-2. Indeed, as seen for 
other human pathogens (Nunes et al., 2013, Martines et al., 2015), the observed cellular tropism doesn’t 
seem to be straight to a particular HSV type. Differences in viral evolutionary dynamics, such as 
evolution rates, can explain why certain viruses have the capacity to adapt to new host species, increase 
in virulence, or develop resistance to antivirals (Hicks et al., 2014). 
In order to contribute for this knowledge, the scope of this thesis was to evaluate the life cycle of 
various genital HSV-1 and HSV-2 clinical isolates with different viral loads in distinct host cell lines, 
giving special focus to the invasion process. Considering that there has been an increase in the number 
of cases of genital herpes caused by HSV-1, especially among the younger population, it is of utmost 
importance to understand whether HSV-1 in the genitalia replicates the same way as it does in mouth 
sores (not evaluated in the present study), or if it has an alternative route of infection that may be similar 
to that of HSV-2. In particular, understanding whether capacities of infections, replication rates, and 
progenies depend on the genital HSV sub-type/strain or on the infected cell line is a mandatory step for 
the understanding of the pathogenesis of human herpes infections and may be important for the 
development of a more effective antiviral chemotherapy.  
To achieve robust and reliable conclusions, four genital HSV samples isolated from genital swabs, 
two HSV-1 and two HSV-2, were used in the present study, as well as three host cell lines with different 
phenotypic and molecular characteristics. Hence, specific objectives of these assays were: 
 
1) To assess whether genital infections caused by HSV-1 and HSV-2 have the same molecular 
characteristics, in a particular cell line; 
 
2) To test if both HSV display the same infection capacity in all three cell lines tested; 
 
3) To measure whether there is a viral saturation in a HSV infection in the three cell lines; 
 
4) To determine the duration of the HSV-1 and HSV-2 life cycle; 
 
5) To determine when does DNA replication begin; 
 


















































2. Materials and Methods 
 
2.1. Biological samples 
The viruses used in the present study were obtained from ulcer and genital/urethral swabs of four 
patients suspected of having a HSV infection, from a Sexually Transmitted Diseases Outpatient Clinic. 
The viral swabs (with viral transport medium) were sent for confirmation of diagnosis to the National 
Reference Laboratory of Herpes simplex virus, Cytomegalovirus and Parvovirus B19 of the Portuguese 
National Institute of Health (INSA), in Lisbon, and treated according to laboratory protocol. After swab 
agitation and content filtration with a 0.45µm filter, DNA was extracted using the automatic nucleic acid 
extractor NucliSENS® EasyMag® (BioMérieux). HSV-1 and HSV-2 DNA was quantified with a 
commercial real-time PCR (RT-PCR) kit (HSV1 HSV2 VZV R-gene®, ARGENE®, BioMérieux), that 
targets a 142 bp fragment of the US7 gene from HSV-1 and a 177 bp fragment of the US2 gene from 
HSV-2. PCR reactions were carried out with the amplification platform ABI PRISM® 7500 (Applied 
Biosystems®). Positive results were reported as copies/mL, taking into consideration sample extracted 
volume, final elution volume and DNA volume used in the amplification reaction. 
The epidemiological, laboratory and clinical data of the selected clinical isolates are described in 
Table 2.1: 
  




Patients information Viral Load 
copies/mL Gender Age Episode Location 
A HSV-1 Female 22 Primary infection 
Vulva, 
perineum 
46 058 248 
B HSV-1 Female 22 Symptomatic reactivation Vulva 87 474 493 
C HSV-2 Male 32 
First symptomatic episode, 
but not primary infection 
Penis 526 335 906 
D HSV-2 Female 24 --- Not available --- Vulva 302 
 
2.2. Cell line handling and maintenance 
The present experimental work was performed using three different adherent epithelial cell lines that, 
due to their susceptibility to a wide range of hosts, are usually used in virology studies, in particular for 
HSV: Vero (ATCC® CCL-81™) and Vero E6 (ATCC® CRL-1586™) from the kidney of the African Green 
monkey, and HeLa229 (ATCC® CCL2.1™) from a cervix adenocarcinoma of a 31-year old black 
woman. Vero E6 cells differ from regular Vero cells since they show some degree of contact inhibition, 
being suitable for supporting the growth of slowly replicating viruses. All cell lines were purchased from 
the American Type Culture Collection. 
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Each cell line was grown in 175 cm3 tissue culture flasks (T175; Sarstedt) with Dulbecco’s Minimum 
Essential Medium (MEM 1x + GlutaMAX™; Gibco, USA) supplemented with 10% fetal bovine serum 
(FBS; Gibco, USA). For both Vero and Vero E6 cells, the medium was further complemented with 1% 
HEPES buffer solution 1M (Gibco, USA), 1% Non-Essential Amino Acids (NEAA 100x; Gibco, USA) and 
0,2% Antibiotic Mixture (PSN 100x; Gibco, USA), while for HeLa229 cells, Gentamicin (50 mg/mL; 
Gibco, USA) and Fungizone (250 µg/mL; Gibco, USA) were added. Cell cultures were incubated in a 
CO2 incubator (Binder) at 37ºC with a 5% CO2 atmosphere, and cellular growth was followed by 
observing cultures under an inverted optic microscope (Leica DMIL LED). 
In order to produce sufficient cellular stocks for all assays, each cell culture was subjected to 
continuous passages whenever a 90% confluent cell monolayer was reached. Briefly, after the medium 
was removed and the cells washed twice with 10 mL of Phosphate Buffered Saline (DPBS 1x; Gibco, 
USA), 5 mL of trypsin (0.5% Trypsin-EDTA 10x; Gibco, USA) were added to the flask, following an 
incubation of 5 minutes in the CO2 incubator, in order to detach the cells. After that time, the cells were 
ressuspended and added to a new flask with fresh medium. 
 
2.3.  Preliminary assays 
For each cell line and HSV isolate, preliminary assays were performed to determine the optimal 
cellular concentration, culture conditions and viral loads to be used for the subsequent quantification 
assays. The inoculation process was also evaluated in order to better mimic an in vivo HSV infection.  
 
2.3.1. Cell counting 
For each cell line, in order to ensure that HSV inoculation occurred on a 90% confluent cell 
monolayer, cell density was verified 24 hours before the assays, using the trypan blue method on a 
hemocytometer (Spencer-Buffalo, USA). Briefly, confluent T175 culture flasks were treated as stated in 
step 2.2 and resuspended; then, 50 µL of the cell suspension were added to 200 µL of Hanks’ Balanced 
Salt Solution (HBSS 1x; Gibco, USA). Following vortex agitation (PV-1 Vortex Mixer, Grant), 50 µL of 
this solution were added to 50 µL of trypan blue (Sigma), which stains dead cells. Finally, 10 μL of this 
solution were placed in each of the two hemocytometer chambers, and the number of viable cells (not 
stained by the trypan blue) were counted under the microscope (Leica DM IL LED). Cell density was 





] =  (
∑ 𝐶𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑞𝑢𝑎𝑑𝑟𝑎𝑛𝑡
4
)  x 104 (Chamber volume x dilution factor) 
 
2.3.2. Culture conditions 
Considering that the success of any microbial infection depends, among other factors, on the 
availability of nutrients in the medium, the optimal FBS quantity to be added to each cell culture was 
determined, in order to guarantee, not only that a confluent monolayer was achieved at the time for the 
experiments, but also that this monolayer was stable enough to support the entire period of a viral 
infection. Basically, suspensions of each cellular culture were seeded into two 24-well plates, with half 
of the wells containing 4% FBS, while the other half had 10% FBS (Figure 2.1). The plates were then 
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placed in a CO2 incubator (Binder) at 37ºC with a 5% CO2 atmosphere, one for 48h and the other for 














Figure 2.1: Nutrient availability assay plate scheme. 
 
2.3.3. Viral stocks 
For each HSV under evaluation, viral stocks were produced by inoculating 100% confluent Vero cells 
monolayers. Infected cells were incubated at 37ºC with a 5% CO2 atmosphere for 1-4 days, until they 
showed cytopathic effect (CPE), i.e., severe morphological alterations in infected cells and lack of 
adherence (Figure 2.2). 
Culture flasks were frozen and defrozen in order to detach all cells from the walls of the flask. Virus 
suspensions were well homogenized, aliquoted into 2 mL tubes and stored at -80ºC, until use. In 
average, a total of 100 mL of stock were produced for each virus. For all four viral stocks, two aliquots 
were randomly selected and subjected to DNA extraction followed by subsequent absolute quantification 
by RT-PCR, as described in 2.1. 
 
 
Figure 2.2: CPE on Vero cells after a one-day incubation with a HSV-2 virus. 
  
The final viral loads, after viral stock production, and based on which further calculations were made 
(for step 2.4) are presented in table 2.2. 
 
 
4% FBS 10% FBS 










Final viral charge 
copies/μL 
A HSV-1 6.05 x 106 
B HSV-1 2.76 x 106 
C HSV-2 2.16 x 107 
D HSV-2 3.68 x 1012 
 
2.3.4. Inoculation conditions 
In order to better mimic the HSV infection in vivo, two different in vitro inoculation conditions were 
tested in parallel: one involved centrifugation and the other agitation. To achieve robust conclusions, 
two HSV-2 clinical isolates, with distinct viral loads (3-fold difference) were used. Briefly, quadruplicate 
24-well plates with confluent Vero cells monolayers were prepared, after adding coverslips to two sets 
of plates. Inoculations were performed by adding 200 μL of each HSV-2 virus per well to 1/3 of the 
wells/plate (Figure 2.3).  
After inoculation, two sets of plates (one with and another without coverslips) were centrifuged at 
700g for 45 min, at 4ºC (Centrifuge 5810 R, Eppendorf), in order to mechanically promote only viral 
attachment to the host cells. At 4ºC, no cellular metabolism occurs, preventing any viral entry. The entry 
process is then synchronized, ensuring that attached viruses will later enter (at a higher temperature) at 
the same time. The other two plates (with and without coverslips) were subjected to agitation at 20 rpm 
for 1 hour (Rocking Platform VWR®), at 37ºC (Memmert), allowing the viruses to attach and possibly 
enter host cells in a less artificial way, at different rates. At the end of both processes, inoculum and 
dead cells were removed, and 1 mL of new media complemented with 4% FBS was added, thus 
accounting time-point “0”. 
Plates were then incubated for ~ 30 hours at 37ºC with a 5% CO2 atmosphere. Infection was followed 
at different time-points (4h, 7h, 9h, 13h, 18h, 23h and 29h p.i.) in order to evaluate the putative HSV 
growth curve. The plates without coverslips were subjected to RT-PCR absolute quantification (Figure 
2.3A) for determining viral load at each time-point, while the others were used for monoclonal antibody 
staining to monitor eventual changes at a cellular level (Figure 2.3B). 
Regarding RT-PCR, the wells were scratched at the indicated time-points of infection and kept at -
20ºC until use. Extractions were later performed using the QIAamp® DNA Blood Mini Kit (Qiagen), 
according to the manufacturer’s instructions. The HSV-2 DNA was amplified and quantified using the 
HSV1/HSV2/VZV R-gene®” ARGENE® kit, as instructed, using the amplification platform ABIPRISM 
7500 (Applied Biosystem). For immunofluorescence, the medium was removed at each time-point, 
washed twice with 1 mL of DPBS and fixed with methanol. After a 10 min air-dry, DPX (Fluka, 
BioChemika) was added for the coverslip to adhere to a slide. 50 μL of the monoclonal antibody specific 
for HSV-2 (Pathfinder™ HSV 1/2, Biorad) were added to the coverslips, following a 30 min incubation 
period in a wet chamber and agitation on a rocking platform (Rocking Platform VWR®). After washing 
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the slides with DPBS, 50 μL of Mounting Medium were added. All slides were later observed in the 




Figure 2.3: Inoculation conditions plate schemes. 
[A] – kPCR plate; [B] – Monocolonal antibody staining plate. 
 
2.4. Evaluation of HSV infection in distinct cell lines  
Once optimization processes regarding inoculation conditions, time-points of infection, cell counting, 
and cell conditions, were established, assays were performed in order to determine the capacity of 
infection of the four viruses under evaluation (Table 2.1), in three distinct cell lines, in terms of progeny 
and infection efficiency. To do this, different multiplicities of infections (MOI) were tested (0.1, 1, 10 and 
100) for each virus, to evaluate if different viral loads had any influence on the success of the infection 
process. To calculate the MOIs, we counted the DNA particles and not the viable viral particles per se, 
as we assumed that by the end of the viral stock preparation all viral replication and assembly had 
already stopped, thus giving rise to infectious viruses, once the monolayer had been completely 
destroyed. 
For each cell line, two 24-well plates with confluent cell monolayers were prepared (as described in 
step 2.3.1; for further information, see Results) and inoculated with each virus at 4 different MOIs (Figure 
2.4). After agitation (step 2.3.4), the inoculum was removed, the wells were washed twice with DPBS 
and 1 mL of fresh media was added, complemented with 4% FBS for Vero and Vero E6 cells, and 10% 
for the HeLa229 cell line. These steps were made in order to guarantee that all the viruses that were 
not able to attach/enter host cells would not affect the infection process. Infected cultures were then 
incubated at 37ºC with a 5% CO2 atmosphere for 30 hours. The infectious cycle was interrupted at 
selected time-points (0h, 6h, 12h, 18h, 24h and 30h p.i.), where cells were harvested and stored at -
20ºC until subsequent extraction and quantification. Time-point “0” refers to the time-point after agitation, 
following the addition of fresh medium. 
A B 




Figure 2.4: Virus inoculation plate schemes. 
Two sets of plates were prepared for each virus per cell line. Time-points were prepared in duplicate. 
Each line corresponds to a different MOI: 0.1 (green), 1 (red), 10 (orange) and 100 (blue). 
 
 
2.5. DNA extraction 
Total DNA was extracted using the QIAamp® DNA Blood Mini Kit (Qiagen), with minor changes 
regarding the given protocol. Briefly, after thawing the samples harvested in step 2.4, the tubes were 
centrifuged at low speed, at 2500 rpm for 5 minutes, in order to isolate non-infected cells and cellular 
debris from viral particles. The supernatant was then collected and from this, 500 µL were added to 50 
µL of Protease or Proteinase K, followed by 500 µL of buffer AL, or ATL, and agitated (Maxi Mixer Vortex 
714). The samples were incubated at 56ºC for 30 minutes in a thermoblock (Thermomixer® Comfort, 
Eppendorf) when using AL, and 15 minutes for ATL. 500 µL of ethanol were added and the whole 
mixture was transferred to a mini-spin column and centrifuged (Sigma 1-14). The columns were washed 
with 500 µL Buffer AW1 and Buffer AW2, with spins between each treatment. Finally, the samples were 
eluted in 100 µL of buffer AE and stored at -20ºC until use. 
 
2.6. Cloning 
In order to develop an in-house HSV-1/HSV-2 RT-PCR system and to design a standard curve for 
RT-PCR experiments, a cloning assay was performed using a single copy gene from each HSV. Two 
genes for each HSV were chosen based of whether they were single copy genes. For HSV-1, a literature 
search (Szpara et al., 2014) was performed to identify highly conserved genes; regarding HSV-2, both 
the US2 and UL27 genes were selected, as the first is the target of the standard HSV commercial kit, 
while the other is often used in the diagnosis and quantification of HSV DNA in the CNS (Tang et al., 
1999). Primers were designed using the Primer Express® Software (Applied Biosystems) and further 
alignments were made using Blast (available in: http://blast.ncbi.nlm.nih.gov/Blast.cgi) to guarantee that 
they were HSV specific and fell in conserved gene regions. The two primers tested for both HSV are 
displayed in Table 2.3. 
 
 
Plate 1 Plate 2 
         0h          6h                   12h       18h      24h      30h  
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Table 2.3: Sets of primers tested. 
Virus Gene Protein Reference 
HSV-1 UL53 Envelope glycoprotein gK (Dolter et al., 1994) 
HSV-1 UL31 Nuclear protein (Szpara et al., 2014) 
HSV-2 UL27 Envelope glycoprotein gB (Tang et al., 1999) 
HSV-2 US2 Tegument protein (Kang et al., 2013) 
 
Primer stock solutions were diluted to a concentration of 25 pmol/μL concentration. DNAs had 
already been extracted and quantified from two HSV clinical isolates (one HSV-1 and one HSV-2) from 
the viral stocks previously prepared (step 2.3.3). DNA serial dilutions were performed based on viral 
load, from a concentration of 1x108 cop/μL up to 1x101 cop/μL. Components for RT-PCR reactions 
(Table 2.4) and PCR conditions (Table 2.5) are described below: 
 
Table 2.4: Pipetting instructions (per reaction). 
Component Volume (µL) 
SYBR Green I 12.5 
Primer F 2 




Table 2.5: PCR cycling conditions. 
Phase Temperature Time Cycles 
Pre-incubation 95ºC 10 min 1 
 
Amplification 
95ºC 15 sec  
40 60ºC 1 min 
 
Melting Curve 
95ºC 15 sec  
1 60ºC 20 sec 
95ºC - 
Cooling 40ºC 30 sec 1 
 
For each HSV, primer selection was based on both efficiency and slope of the obtained HSV standard 
curves. Primers where the respective calibration curve presented a slope of approximately - 3.3 and an 
efficiency of nearly 100% were chosen (Svec et al., 2015). 
Once chosen the fittest primers, new RT-PCR reactions were performed to amplify the two conserved 
gene fragments, one for each HSV, using the Thermo Scientific Phusion High-Fidelity DNA Polymerase 
kit (Thermo Fisher): UL31 for HSV-1 and UL27 for HSV-2. The set of primers used for this reaction 




Table 2.6: Location and sequence of the primers used to amplify the desired DNA fragments. 
 
Table 2.7: Pipetting instructions (per reaction). 
Component Volume (µL) 
Phusion DNA Polimerase 0.5 
5xPhusion HF Buffer 10 
10 mM dNTPs 1 
Primer F 2.5 
Primer R 2.5 
H2O Up to 50 µL 
 
Table 2.8: Real-Time PCR cycling conditions. 
Phase Temperature Time Cycles 












Final extension 72ºC 5-10 min 1 
 
Then, the desired fragment was inserted in a linearized cloning vector (plasmid) through a ligation 
reaction using the CloneJET PCR cloning Kit (Thermo Fisher). A mixture was prepared with 10 µL of 
Reaction Buffer, 0.5 μL of the amplified PCR product (pPCR), 1 μL of pJET1.2/blunt Cloning Vector 
(Figure 2.5), 1 μL of T4 DNA ligase and 6.5 µL of nuclease-free Water, followed by an overnight 




Figure 2.5: pJET1.2/blunt vector map.  
Gene Primer Forward Primer Reverse Amplicon  
UL31 CTCACGCCCGCAAACAG CGAAAAGGCCCCGATAGC 60 bp 
UL27 GCGGTGGTCTTCAAGGAGAA CACGGTCACGTCTTTGTAGTACATG 72 bp 
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For the transformation of electro-competent E.coli cells, 5 μL of the ligation reaction were added and 
the cells were left for overnight growth at 37ºC. Since only the cells with the vector have the ability to 
grow, all colonies were harvested and grown in LB-agar medium with ampicillin (100 µg/µL) overnight.  
Confirmation of transformation was achieved by Sanger sequencing. 
Plasmids were purified using the PureLink™ Quick Plasmid Miniprep Kit (Invitrogen), according to 
the manufacturers’ instructions. Briefly, the overnight LB-culture was centrifuged and the entire medium 
was removed. 250 µL of Ressuspension Buffer (R3) with RNase were added, followed by 250 µL of 
Lysis Buffer (L7) and an incubation of 5 minutes at room temperature. 350 µL of Precipitation Buffer 
(N4) were added, and the lysate was centrifuged for 10 minutes. The whole mixture was then transferred 
to a spin column and treated with 500 µL of Wash Buffer (W10 and W9), with spins between each 
treatment. Finally, the samples were eluted in 75 µL of TE Buffer. Plasmids were quantified by reading 
absorbance at 260 nm with the Qubit® and concentrations analyzed following tables 2.9 and 2.10 and 
equation 2.  
 
Table 2.9: Absorbance reading and plasmid quantification. 
Virus Dilution Concentration (ng/µL) Concentration (g/µL) 
HSV-1 1:4 7.33 7.33 x 10-9 
HSV-2 1:4 5.56 5.56 x 10-9 
 
Table 2.10: Determination of plasmid molecular weight. 
Virus Sequence size (bp) Molecular Weight* (Da) 
Plasmid concentration 
(nº plasmids/µL) 
HSV-1 3034 1871796 2358285437 
HSV-2 3046 1879327.02 1781653901 
 
Note: The molecular weight of each plasmid was calculated using free software available at: 
http://www.currentprotocols.com/WileyCDA/CurPro3Tool/toolId-8.html. * 1 Da = 1 g/mol 
 
(2) [𝑃𝑙𝑎𝑠𝑚𝑖𝑑](𝑛º 𝑝𝑙𝑎𝑠𝑚𝑖𝑑𝑠/µ𝐿) =




In order to obtain a calibration curve, the first dilution is made at 1x107 plasmids/µL, followed by serial 
dilutions of 1:10, up to a concentration of 1x100 plasmid/µL. 
 
2.7. Absolute Quantification assays 
For extracted viral samples, RT-PCR absolute quantifications were performed, using the standard 
curve method, with primers regarding the UL31 gene for HSV-1 samples and the UL27 gene for HSV-
2. Reactions conditions and reagents are displayed in Tables 2.4 and 2.5 above. All reactions were 
performed using the LightCycler®480 Real-Time PCR System (Roche, USA). For all cell lines, each 96-















































3. Results  
 
3.1. Preliminary assays 
Before evaluating the HSV infection in distinct cell lines (HeLa229, Vero and Vero E6), preliminary 
assays were performed to establish the optimal experimental conditions to be applied, hence ensuring 
that the main assays mirrored an in vivo HSV infection, as best as we could control. 
One of the first aspects to be evaluated regarded the cellular concentration that needed to be 
previously added to each 24-well plates, in order to guarantee that HSV inoculation occurred on a stable 
90% confluent cell monolayer able to support the entire infection cycle. For all cell lines, an optimal 
concentration of 3x105 cells/well was found to be required to obtain a stable confluent cell monolayer, 
after periods of 20-24 hours for HeLa229 cells, and 30-36 hours for both the Vero and Vero E6 lines 
(data not shown). 
Once established the ideal cellular concentration, we next determined the sufficient FBS quantity to 
nutritionally complement the culture medium without promoting an over-proliferation of cell cultures. 
Considering that both Vero and Vero E6 cells display a higher growth rate than HeLa229 cells, and have 
tendency to vertically overlap, smaller quantities of FBS had to be added to the culture medium to obtain 
stable confluent monolayers at the time of the experiments. Whereas for HeLa229 cells, 10% of FBS 
was used, for both Vero and Vero E6 cells, 4% was found to be sufficient (data not shown). 
We then sought to evaluate the ideal inoculation modus operandi (centrifugation vs. agitation), so 
that the success of the inoculation process was guaranteed, while maintaining it as less artificial and 
stressful as possible for mimicking an in vivo infection. For higher robustness, two HSV-2 clinical 
isolates, differing ~2.5-times in viral load (which corresponds to MOIs of ~40 [Sample 1] and ~100 
[Sample 2]), were used. Regardless the inoculation modus operandi tested, the two HSV-2 isolates 
seem to exhibit a similar infectious/life cycle pattern of ~23 hours, time where viral progeny peaks for 
both isolates, apparently stabilizing after that (Figure 3.1). In addition, the HSV infection does not seem 
to be influenced by viral load when centrifugation is performed (Figure 3.1A), contrarily to that observed 
with agitation, where differences ranging from 2.2- to 5.3-fold were detected throughout the infectious 
cycle among the two HSV-2 clinical isolates (Figure 3.1B). These findings were also supported by 
comparing each infection between the two inoculation processes (Figure 3.2). Although no differences 
were seen until 9 hours p.i. for both HSV-2 isolates, a different scenario was observed after this time-
point for the virus with the lowest load (Figure 3.2A). Significant discrepancies were seen in this case, 
where 3-fold higher progenies were obtained, in average, for centrifugation when compared with 
agitation. This was not surprising, as centrifugation mechanically forces viral attachment to the host 
cells, and at 4ºC no cellular metabolism occurs, avoiding any viral entry. The entry process is hence 
synchronized, ensuring that, at higher temperatures, some of attached virus will later enter at the same 
rate. In opposition, agitation at 37ºC allowed both the viral attachment and entry into the host cells at 
different rates. On the other hand, when HSV-2 viral load is higher, infection efficiency seems to be 
similar among the two inoculation processes (Figure 3.2B), as progenies generated throughout the cycle 
were analogous, suggesting that viral load may be a critical factor for the success of the HSV-2 infection, 
at least for the tested Vero cell line. These preliminary RT-PCR absolute quantification results were 
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further supported by immunofluorescence assays (performed in parallel), where Vero cell alterations 
could be seen as HSV-2 infection progressed, being slower with agitation (Figure 3.3) and lower viral 
loads (data not shown).  
 
 
Figure 3.1: Growth curves of two HSV-2 clinical isolates with different viral loads. 
[A] – Centrifugation; [B] - Agitation 
Confluent cell monolayers were infected with two viral samples and incubated for 29 hours at 37ºC 
and a 5% CO2 atmosphere. Cells were harvested at different time points in order to assess progeny 
and compare the two processes. 
 
 Figure 3.2: Growth curves of two HSV-2 samples with different viral loads. 
[A] – Sample 1; [B] – Sample 2. 
Confluent cell monolayers were infected with two HSV-2 samples and incubated for 29 hours at 37ºC and a 
5% CO2 atmosphere. Cells were harvested at different time points in order to assess progeny and compare 


























































































































Figure 3.3: Evolution of a HSV infection over time, in a monoclonal antibody staining assay. 
Cells were stained with monoclonal antibodies at the indicated time-points of infection. Uninfected cells are 
stained in red, and infected cells can be seen as fluorescent green. Over time, the number of cells 
diminishes, and in the end, there are almost no cells left, as a HSV infection lead to cell lysis.  
 
3.2. Evaluation of HSV infections in distinct cell lines 
Considering the preliminary results for the HSV-2 subtype in Vero cell line, likely pointing viral load 
as an important player in the efficiency of the infection, further studies were conducted using two other 
HSV-2 (C and D) and two HSV-1 (A and B) clinical isolates at four different MOIs (0.1, 1, 10 and 100), 
as well as two additional cell lines (HeLa229 and Vero E6) exhibiting different phenotypic and molecular 
features. We can assume that similar initial concentrations of each virus were added to all plates for a 
specific MOI and for each cell line. 
In order to assess if both capacity and efficiency of HSV infection depend on the HSV subtype/strain 
and/or on the infected cell line, RT-PCR absolute quantifications were performed throughout multiple 
time points of infection (0h, 6h, 12h, 18h, 24h and 30h) in each cell line. Based on both slopes and 
efficiencies of calibration curves (see “Material and Methods” for details), primers regarding the UL27 
and UL31 genes were selected for RT-PCR absolute quantification of HSV-2 and HSV-1 strains, 
respectively. 
Unpredictably, contrarily to preliminary assays, the HSV life cycle was longer, and at 30 hours p.i. 
there was not a viral load stabilization, indicating that DNA continued to be synthesized for all viral 
isolates, in the three cell lines (including the previously tested Vero cell line).  
3.2.1. HSV-2 infections 
Unexpectedly, for the three cell lines (including the previously tested Vero cell line), the life cycle 
observed for the two HSV-2 clinical isolates (C and D) was longer than that found in the preliminary 
assays. Indeed, no viral load stabilization was seen at 30 hours p.i., indicating that DNA continued to be 
synthesized for all viral strains. Considering that clinical isolate C was used in the preliminary assays at 
MOI of 100 (isolate 2), we would expect that, at least for this virus, the infectious process would have 
had, approximately, the same duration. However, this was not observed. The reason for this may be 
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due to viral stock preparation before the experiments, where the virus was subjected to multiple rounds 
of freezing/thawing, likely impacting both the infectiousness and rate of viral infection, when inoculations 
were performed using a viral aliquot immediately after thawing. In opposition, in the preliminary assays, 
this isolate was directly used without any step of freezing/thawing.  
For clinical isolate D, regardless the cell line used, continuous microscopic observation for each MOI 
revealed no significant CPE during the period under evaluation. Curiously, no viral particles were 
apparently quantified by RT-PCR assays (data not shown). Considering that standard curves (present 
in the same plate as extracted DNA samples at each time-point for each MOI and for each cell line) 
were generated, one can discard the occurrence of any problem in the RT-PCR reactions or selected 
primers. The only plausible explanation points to a failure in the infection process (possibly due to virus 
viability loss). As all the inoculum was removed in each condition, no viral particles remained in the 
culture to be later extracted and detected by RT-PCR assays. For this reason, this clinical isolate was 
discarded from this study. 
On the other hand, for clinical isolate C, evident CPE could be observed microscopically from MOI 
of 1, where damages were visible at 30 hours p.i. for all cell lines (Figure 3.4), to MOIs of 10 and 100, 




Figure 3.4: HSV-2 isolate C infection in vitro, at a MOI of 1, 30 hours p.i. 
 
Regarding HSV-2 isolate C, at 0h p.i. (Figure 3.5), time period when host cell attachment is thought 
to occur, the Vero E6 cell line always presented the lowest viral concentrations, regardless the MOI, 
while similar attachment rates were seen in both HeLa229 and Vero cells, with the exception of MOI of 
0.1. Moreover, DNA appears to have always been synthesized earlier (mostly at 6h p.i.) in the Vero E6 
cell line for all MOIs (Figure 3.6), with a lag of ~6h (at least) when compared to both HeLa229 and Vero 
cells. The only exception occurred for MOI of 1, where this isolate displayed similar behavior in both 
HeLa229 and Vero E6 cells. Curiously, despite the disparities in the observed attachment capacities, 










Figure 3.5: HSV-2 isolate C growth curves in HeLa229, Vero and Vero E6 cells at four MOIs. 
[A] – MOI 0.1; [B] – MOI 1; [C] – MOI 10; [D] – MOI 100. 
Confluent cell monolayers were infected with the indicated virus at four distinct MOIs in HeLa 299 (blue), 






















































































































Figure 3.6: HSV-2 isolate C growth curves in distinct cell lines, at four different MOIs. 
[A] – HeLa229 line; [B] – Vero line; [C] – Vero E6 line. 
Results were analyzed in terms of MOI, in each cell line. MOIs of 0.1 (orange), 1 (yellow), 10 (green) and 
100 (red) were compared between to two samples. Viral load values are expressed on a logarithmic scale. 
 
3.2.2. HSV-1 infections 
For both clinical isolates (A and B), HSV-1 life cycle did not seem to end at 30h p.i. for all cell lines 
regardless MOI, as no viral stabilization was achieved until this time-point, as seen for HSV-2 clinical 
isolate C.  
Little cellular destruction was microscopically observed for both HSV-1 clinical isolates at MOIs of 
0.1 and 1 (Figure 3.7), even at 30h p.i.. On the other hand, for MOIs of 10 and 100, cellular damages 
were observed as soon as 6/12 hours p.i. for all cell lines, with total CPE visible at 30h p.i.. These 
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Figure 3.7: HSV-1 infection in vitro.  
[A] – HSV-1 infection (isolate A) in Vero cells, at a MOI of 1, 30 hours p.i. 
[B] – HSV-1 infection (isolate A) in Vero E6 cells, at a MOI of 1, 30 hours p.i. 
 
At a MOI of 0.1 (Figure 3.8), both HSV-1 clinical isolates (A and B) seemed to have lower attachment 
affinities towards HeLa229 cells when comparing to the remaining cell lines. DNA started to be 
synthesized at 12h p.i., except for clinical isolate A, where synthesis in Vero cells began earlier, 6h p.i.. 
At 30h p.i., similar DNA particles had been originated for almost all cell lines, although higher viral loads 
were found for clinical isolate A in HeLa229 cells. 
 
Figure 3.8: Clinical isolates A and B growth curves in the three cell lines, at a MOI of 0.1. 
[A] – Clinical isolate A; [B] – Clinical isolate B. 
Confluent cell monolayers were infected with the indicated virus at a MOI of 0.1 in HeLa 299 (blue), Vero 
(orange) and Vero E6 (grey) cells.  Viral load values are expressed on a logarithmic scale. 
 
On the other hand, a slightly different attachment scenario was seen for MOIs of 1, 10 and to a lesser 
extent 100 (Figure 3.9), where both HSV-1 clinical isolates exhibited lower attachment affinities towards 
Vero E6 cells comparing to the remaining cell lines. For both clinical isolates, DNA generation appears 
to begin at 6h p.i. for both HeLa229 and Vero E6 cells regardless MOI, whereas a delay of ~6h was 
seen for Vero cell line (Figure 3.10). At 30h p.i., clinical isolate B seemed to generate similar DNA 
molecules regardless cell line, while higher viral loads of clinical isolate A were always found for 



























































Figure 3.9: HSV-1 isolates A and B growth curves in the three cell lines, at MOIs of 1, 10 and 100. 
 [A] –Clinical isolate A, MOI 1; [B] - Clinical isolate A, MOI 10; [C] – Clinical isolate A, MOI 100; 






































































































































































Figure 3.10: HSV-1 isolates A and B growth curves in the three cell lines, at four different MOIs. 
[A] – HeLa229, Clinical isolate A; [B] - Vero, Clinical isolate A; [C] – Vero E6, Clinical isolate A; 
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3.3. Evaluation of HSV infection yields in distinct cell lines 
In order to assess infection efficiency, virus yields were calculated based on the initial and final viral 
loads for each sample. For clinical isolate C, the Vero E6 cell line seemed to be the most appropriated 
one for HSV-2 growth, always exhibiting efficiency rates considerably higher for all MOIs, including a 
remarkable value of ~626 for MOI 10 (Table 3.1; Figure 3.11). In fact, for this MOI, yield values regarding 
viral growth in the Vero E6 cell line were 20 and 70 times higher when compared to those of HeLa229 
and Vero cells, respectively.  
For both HSV-1 clinical isolates, higher infection efficiencies were clearly obtained in HeLa229 cells, 
with higher values (~270 and 219 for isolate A and B, respectively) at MOI 0.1. Curiously, for increasing 
MOIs, lower efficiency rates were observed in this cell line. 
Overall, worst viral infection yields were always observed for the Vero cell line regardless MOI, with 
values ranging from ~ 4 to 26. 
Table 3.1: Viral yield values for each sample, in three distinct cell lines and four MOIs. 










 HeLa229 276,36 55,15 21,45 18,37 
Vero 3,79 3,91 4,80 9,83 










 HeLa229 219,71 6,08 6,74 7,67 
Vero 10,94 7,11 10,04 9,23 










 HeLa229 8,56 40,35 29,57 25,98 
Vero 25,93 9,58 8,63 8,59 

















Figure 3.11: Viral yield at four MOIs. 
[A] – MOI 0.1; [B] – MOI 1; [C] – MOI 10 [D] – MOI 100. 
Yield values were evaluated in HeLa229 (blue), Vero (orange) and Vero E6 (grey) cells, for the four MOIs. 










































































































































Genital herpes is currently one of the most prevalent STIs worldwide (Smith et al., 2002). However, 
despite the fruitful research performed in the later years, we are still far from understanding the 
molecular features underlying HSV genital infections, as viral cellular tropism appears to be not as 
restrictive as traditionally assumed. Indeed, there has been an increase in the number of primary genital 
infections caused by HSV-1 (usually associated with oro-facial lesions), even though HSV-2 still remains 
the most prevalent subtype found in genital herpetic lesions. Therefore, in order to contribute for the 
understanding of the pathogenesis of human herpes genital infections, the current MSc thesis intends 
to evaluate whether HSV subtype/strain and/or infected tissue impacts both capacity and efficiency of 
viral infection, in terms of replication rate and progeny.   
 Concerning the HSV life cycle, no consensual literature was found, as some authors claim that 
HSV is able to infect and lyse host cells within 15 hours (Jenkins et al., 1996, Lehman et al., 1999, Tang 
et al., 1999), while others reported processes of ~24 hours (Roizman et al., 2003, Schiffer et al., 2013). 
Our preliminary assays corroborate the later, as infection cycles of ~23 hours were obtained. However, 
in our main assays, longer infectious cycles were seen (~30h), which could be explained by the multiple 
rounds of freezing/thawing in the viral stock preparation, likely impacting both the infectiousness and 
rate of viral infection (GREIFF et al., 1954, Pinsky et al., 2003, Hansen et al., 2005)  
For all HSV-1 and HSV-2 clinical isolates, similar infection patterns were observed for every MOI 
except 0.1, regardless cell line. Despite dissimilar viral loads seen at 0h p.i., the observed consecutive 
10x load increments for higher MOIs (Tables A2-4 from Appendix 2) suggest that initial viral 
concentrations do not appear to affect adherence to host cells. Nevertheless, for a MOI of 0.1, HSV-2 
attachment efficiency was 70x lower than that observed for both HSV-1 isolates, with a difference ~140x 
lower at the highest MOI of 100. Corroborating this, Trybala et al. (Trybala et al., 2000) showed that 
both HSVs display different affinities towards the HS molecule, is essential for the viruses initial binding. 
These differences were also seen by Vahlne et al. (Vahlne et al., 1980), who demonstrated that HSV-1 
virions were more easily adsorbed that those of HSV-2 for a specific cell type. 
We do not know whether attached viruses are able to effectively enter into host cells, neither if the 
host cell is permissive to the infection of more than one virus. As a HSV infection causes multiple 
alterations in the cell surface, such as membrane modifications and loss of matrix binding proteins 
(Blaho et al., 2005), it is possible that more than one virus infects a single cell, by taking advantage of 
the cell’s deterioration. At a MOI of 0.1, where we have 10 cells for each virus, we can assume that 
almost every virus was able to entry into a host cell and originate high progeny. This assumption was 
not so intuitive for higher MOIs, since we don’t know whether one viral particle gives rise to 1 or 100 
progeny virions. 
For all HSV-1 and HSV-2 clinical isolates, DNA started to be synthesized nearly 6-12h p.i., 
increasing throughout the cycle until it peaked, stabilizing or decelerating after that due to a higher viral 
assembly and release (Figure 3.6; 3.10). Curiously, until DNA synthesis began, viral concentrations 
were found to first decrease during a ~6h-period in almost all assays, regardless the MOI and cell line. 
Similar behaviors had been already reported in the literature (Nicola et al., 2004), where this apparent 
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temporary decrease was presumed to represent virion gradual degradation and not penetration into the 
cytosol. During this ~6h time-period, we believe that HSV replication starts to take place, often with 
simultaneous generation of infectious progeny virus. To support this, replication periods between 3-6h 
p.i. and 12-18h p.i. have been reported in the literature (Blaho et al., 2005, Ikeda et al., 2011). On the 
other hand, monolayer destruction seems to be phenotypically different between HeLa229 and both 
Vero and Vero E6 cells, with CPE in the later being characterized by a random cell concentration in the 
monolayer that continuously spreads until total cell lysis (Figure 3.4), while CPE in HeLa229 cells 
appears to have a uniform cellular infection distribution in the monolayer that ends up with cell lysis. 
Considering that HeLa229 is a human epithelial cell line isolated from a cervix adenocarcinoma whilst 
Vero/Vero E6 cells are isolated from kidney    cells extracted from an African green monkey, we can 
speculate whether the last are a good in vitro model to mimic genital infections in vivo.  
Regarding viral infection capacity in all three host cell lines, Vero E6 cells seem to be 
unquestionably the most appropriated ones for HSV-2 growth, always exhibiting efficiency rates 
considerably higher for all MOIs, where differences of up to 6-fold were seen for MOI 10 when compared 
with the lowest value given by MOI 0.1 (~626 versus ~97) (Table 3.1; Figure 3.11). On the other hand, 
HeLa229 cells appeared to be the most suitable for HSV-1 infection at the lowest MOI, indicating that 
the replication success is higher for smaller inoculums. This yield decreases with the increase of the 
MOIs (Table 3.1; Figure 3.11). There seems to be some kind of inhibitory process that does not allow 
the viruses to replicate at such a higher pace as that for smaller MOIs (Figures 3.6; 3.10; 3.11). One 
option is the fact that a lot of viruses appear to attach to the cell’s surface, but only a small percentage 
have the ability to penetrate it and initiate the replication cycle. On the other hand, it is possible that the 
same number of viruses enter a host cell, but replication rates suffer some kind of inhibition/saturation, 
making the process not as efficient. Nevertheless, as mentioned before, it does not seem that an 
increase in the inoculum poses as an inhibition to virus attachment, since all attached cells can be 
accounted for. Overall, in the described conditions, the Vero cell line had the worst viral growth results 
regardless MOI, displaying the lowest replication rate yields (Table 3.1; Figures 3.11). This does not 
coincide with the literature, where viral yields were shown to be similar in both Vero and HeLa229 cells 
(Nicola et al., 2003). It was also demonstrated that HSV-1 grew to between 2 and 5 times higher titers 
in Vero cells when compared with HeLa229 cells, suggesting a faster viral growth (Nguyen et al., 2005). 
The most plausible explanation for the occurred relies on the fact that high-passage Vero cell flasks are 
commercially purchased, so that no more than 4-5 passages are made, before losing cell properties. 
This parallels a previous study performed for another cell line (Hampar et al., 1965), where it was stated 
that, beyond 10 passages, the time required for complete HSV cell destruction after a viral infection 
increased. On the other hand, a decrease in productive viral replication can occur when cells are left 
more than a day after reaching confluency prior to an infection. It was seen that, when Vero cells reached 
100% confluency and were not passed or infected, they would vertically overlap and/or die (Ammerman 
et al., 2008). 
Although there are multiple studies that intended to evaluate putative differences in HSV subtypes 
infectivity, none of them is conclusive, being sometimes contradictory. For instance, while some authors 
argue that HSV-1 generally grows to a higher pace than HSV-2 (Docherty et al., 1971), others state that 
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HSV-2 strains generally show faster and more complete shut off of host protein synthesis than HSV-1 
strains (Aguilar et al., 2006). Regardless MOI and host cell line, our results showed that HSV-2 always 
exhibits lower attachment capacities than HSV-1, apparently growing at a slower pace throughout the 
infection cycle (Figures 3.5; 3.8; 3.9). However, concerning viral DNA synthesis, discrepancies among 
HSV subtypes were only seen between cell lines. Indeed, for instance, HSV-2 seemed to always yield 
more progeny virions than both HSV-1 clinical isolates in Vero E6 cells (Table 3.1; Figure 3.11). Although 
we cannot state that this higher HSV-2 infection success might occur in vivo, it is not nonsense to 
speculate that, in genitalia, HSV-2 may have acquired evolutionary strategies allowing a better host 
immune evasion than for the recently emerging HSV-1 genital herpes, which may be not yet adapted to 
this biological niche. Nevertheless, for both HSV subtypes in general, progeny appears to have been 
generated earlier (mostly at 6h p.i.) in the Vero E6 cell line for all MOIs, while for the remaining cells 
(HeLa229 and Vero) progenies were mostly seen with a lag of ~6h (at least) (Figures 3.6; 3.10). 
In the future, biological replicas should be made, in order to further confirm the obtained results. To 
do this, all the assays should be repeated, using a different aliquot from the viral stocks produced. In 
addition, other cells lines could be studied, namely MRC-5. This is a fibroblastic cell line, often used in 
HSV studies, commonly used for shell vial tests, for HSV detection; however, it is frequently used for 
CMV in INSA, but not for HSV, hence not being used as an additional tested cell line. 
We also intend to study in vitro selective pressure. As mentioned before, it is possible that multiple 
passages in the Vero cell line in vitro can affect their viability, one possible reason for the results 
obtained. Genomic studies should also be made of both HSV sub-types, to determine if the viruses 
developed some kind of resistance to growth on Vero cells. 
Viral stocks were only prepared in the Vero cell line. This was due to the fact that Vero cell line is the 
preferential line for HSV studies. Nevertheless, it is not known whether viral propagation in different cell 
lines would lead to differences in infections capacities in the respective cell line. So, we also intend to 
produce viral stocks Vero E6 and HeLa229 cells. 
Finally, one additional study should be made regarding freezing and de-freezing viral stocks, in order 
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Appendix 1 – Standard and amplification curves 
 
 



















Figure A.5: UL27 amplification curves. 
 
 






Figure A.7: US2 amplification curves. 
 
 




















Appendix 2 – Preliminary assays kPCR results 
 













4h 8,61 x 106 1,92 x 107 
7h 1,08 x 107 1,88 x 107 
9h 3,66 x 107 1,35 x 107 
13h 1,16 x 108 2,70 x 107 
18h 1,86 x 108 5,36 x 107 
23h 2,80 x 108 1,05 x 108 








4h 2,75 x 107 6,57 x 107 
7h 4,03 x 107 4,14 x 107 
9h 7,60 x 107 7,26 x 107 
13h 1,55 x 108 1,22 x 108 
18h 2,32 x 108 1,66 x 108 
23h 4,32 x 108 2,87 x 108 























Appendix 3 – qPCR results 
 




































0h 1,10 x 105 7,34 x 106 1,55 x 108 1,69 x 109 
6h 8,32 x 104 3,59 x 106 6,22 x 107 6,82 x 108 
12h 9,28 x 104 1,00 x 107 9,78 x 107 1,32 x 109 
18h 1,68 x 106 3,59 x 107 3,54 x 108 3,23 x 109 
24h 1,41 x 107 1,21 x 108 1,59 x 109 1,19 x 1010 





0h 1,90 x 106 1,48 x 107 1,47 x 108 7,55E x 108 
6h 1,01 x 106 7,36 x 106 9,58 x 107 1,20 x 109 
12h 3,15 x 106 4,14 x 106 8,54 x 107 1,08 x 109 
18h 8,60 x 105 1,09 x 107 1,38 x 108 1,35 x 109 
24h 5,12 x 106 2,47 x 107 2,99 x 108 2,02 x 109 







0h 7,22 x 105 1,86 x 106 3,37 x 107 3,76 x 108 
6h 3,65 x 105 1,10 x 106 7,62 x 106 6,62 x 107 
12h 1,63 x 105 1,70 x 106 1,71 x 107 1,45 x 108 
18h 1,15 x 106 6,28 x 106 6,48 x 107 8,08 x 108 
24h 2,53 x 106 2,91 x 107 2,82 x 108 2,22 x 109 



























































0h 1,40 x 105 2,29 x 107 1,85 x 108 1,23 x 109 
6h 2,41 x 105 3,59 x 106 3,94 x 107 6,22 x 108 
12h 3,91 x 105 4,99 x 106 4,96 x 107 4,82 x 108 
18h 3,05 x 106 1,56 x 107 1,61 x 108 1,49 x 109 
24h 6,68 x 106 4,30 x 107 4,70 x 108 4,70 x 109 





0h 2,81 x 106 4,01 x 107 3,11 x 108 2,17 x 109 
6h 3,46 x 106 2,37 x 107 2,08 x 108 3,30 x 109 
12h 1,37 x 106 2,30 x 107 1,99 x 108 2,57 x 109 
18h 9,16 x 106 5,30 x 107 5,04 x 108 5,03 x 109 
24h 1,44 x 107 1,30 x 108 1,45 x 109 9,78 x 109 







0h 8,08 x 105 3,29 x 106 3,29 x 107 4,68 x 108 
6h 6,14 x 105 1,73 x 106 1,10 x 107 1,49 x 108 
12h 8,78 x 105 4,75 x 106 3,54 x 107 4,08 x 108 
18h 1,97 x 106 2,25 x 107 1,38 x 108 1,63 x 109 
24h 6,80 x 106 7,26 x 107 7,40 x 108 5,26 x 109 





























































0h 3,06 x 104* 8,68 x 104 1,17 x 106 8,96 x 106 
6h 3,06 x 104 1,72 x 104 1,02 x 106 8,44E x 106 
12h ** 1,23 x 105 1,16 x 106 8,92 x 106 
18h 3,39 x 104* 6,22 x 105 2,58 x 106 3,96 x 107 
24h 2,14 x 105 2,80 x 106 1,32 x 107 1,39 x 108 





0h 5,70 x 103 1,83 x 105 1,70 x 106 1,37 x 107 
6h 1,88 x 104 7,21 x 104 7,66 x 105 1,58 x 107 
12h 1,07 x 104 8,40 x 104 5,12 x 105 8,74 x 106 
18h 1,22 x 104 2,86 x 105 1,72 x 106 1,95 x 107 
24h 6,66E x 103 9,20 x 105 8,62 x 106 5,44 x 107 







0h 1,63 x 103* 8,48 x 103 5,42 x 104 1,00 x 106 
6h ** 2,39 x 103 5,30 x 104 5,98 x 105 
12h 1,63 x 103 9,08 x 103 1,85 x 105 3,89 x 106 
18h 2,42 x 104 2,07 x 105 2,10 x 106 2,12 x 107 
24h 6,36 x 104 6,46 x 105 1,54 x 107 1,12 x 108 
30h 1,59 x 105 1,90 x 106 3,39 x 107 1,44 x 108 
 
 
* For growth curve generation, to these points was given the viral load quantified in the next 
time-point; 
** Results were inconclusive 
 
